replimune.com - REPL Income before deduction of interest, taxes and amortization
The prospects for Replimune Group, Inc. (REPL) are based on the market launch of unique immunotherapeutic drugs against tumors. This GURU.Markets terminal chart, illustrating EBITDA where 0.00 records a new level, confirms the risks of negative leverage during the testing phase. The scalability growth of the RP1 platform and FDA approval will be the decisive factors for commercial patient reach.
Replimune - analytical breakdowns and key metrics (REPL)
- market value and analyst target forecast:
- issuer market value details:
- book capitalization information:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
REPL - Net Income|Future Net Profit Replimune Group, Inc.|REPL - P/E Multiple|Future Price to Earnings Multiple replimune.com|REPL - PEG Multiple|Company Value to EBITDA Replimune|REPL - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Replimune|REPL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth replimune.com|REPL - Earnings per share growth in current year|Net earnings per share change forecast for next year Replimune Group, Inc.
Analysis of all company metrics:Replimune Inc. - REPL
Absolute EBITDA measures the actual cash flow from core operations, excluding non-cash charges and tax adjustments to assess true financial stability. By analyzing absolute EBITDA trends, an investor can project the future profitability of Replimune Group, Inc. (REPL), considering the potential for low cost of goods sold during mass production of drugs based on their scalable immuno-oncology platform.
Competitors of Replimune Group, Inc. (REPL)
NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Lyell LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology, Inc.) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization iobiotech.com (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization KA (kinetabio.com)|NEXI: Operating profit EBITDA|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Profit before payment of interest, taxes and amortization Vaccinex, Inc|Harpoon Therapeutics Corp - Profit before deduction of interest, taxes, depreciation and amortization
